GlassScriptPhysician profile
Armando Garcia
NPI 1063552214
$5,343.42
in general payments reported to CMS, 2019-2025
20 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $200 · 2022: $338 · 2023: $935 · 2024: $2,870 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,503 · Travel and Lodging: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,502.70 |
| Travel and Lodging | $1,302.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,384.15 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Globus Medical, INC. | $495.15 | 2025 | Senza, Vyrsa Fix, Vyrsa V1 |
| Nevro Corp. | $455.10 | 2023-2024 | Senza |
| Medtronic, INC. | $252.30 | 2021-2025 | Vectris Surescan, Inceptiv, Synchromedii |
| Nalu Medical, INC. | $191.30 | 2022-2025 | Nalu Neurostimulation System |
| Abbott Laboratories | $156.14 | 2021-2024 | Proclaim, Eterna |
| Pfizer INC. | $64.44 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.11 | 2021-2024 | Relistor |
| Averitas Pharma INC. | $44.14 | 2024-2025 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $42.63 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $41.48 | 2021 | |
| Lilly USA, LLC | $28.86 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $21.49 | 2023 | Zilretta, Iovera |
| Grt US Holding, INC. | $18.37 | 2022 | |
| Vertos Medical, INC. | $17.39 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $17.07 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.23 | 2021 | |
| Collegium Pharmaceutical, INC. | $14.59 | 2024 | Belbuca |
| Abbvie INC. | $14.50 | 2021 | |
| Spr Therapeutics, INC | $11.98 | 2023 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armando Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.